Metformin XR, 500- nocte

PreclinicalSmall molecule

Metformin XR, 500- nocte is one of 25 small molecule programs targeting Type 2 Diabetes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Preclinical

5 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 3

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 4

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Lovaza

AstraZeneca

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

GLP-1

RRigshospitalet, Denmark

Preclinical

1 10

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Cognitive Decline

NCT04511416

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes

Completed·GGarvan Institute of Medical Research·N/A·NCT03558867·138 enrolled

Cognitive Decline1 trial

Preventing Cognitive Decline with Metformin

Active, not recruiting·GGarvan Institute of Medical Research·Phase 3·NCT04511416·242 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Metformin XR, 500- nocte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metformin XR, 500- nocte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metformin XR, 500- nocte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Garvan Institute of Medical Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGarvan Institute of Medical Research

Metformin XR, 500- nocte

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Type 2 Diabetes1 trial

Cognitive Decline1 trial

References

Drug Info

Quick Facts

Related News